BMEA — Biomea Fusion, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840439 ·
Last close
$1.41
Market Cap
$101.94M
52W High
$2.24
52W Low
$1.07
ADV30
1,501,030
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | — | — | 46,385,000 | 44,693,000 | 27,666,000 |
| Dec 2025 | 0 | — | -11,719,000 | 4,612,000 | 58,572,000 | 55,812,000 | 29,020,000 |
| Sep 2025 | 0 | — | -18,600,000 | -16,407,000 | 55,187,000 | 46,642,000 | 39,568,000 |
| Jun 2025 | 0 | — | -21,276,000 | -20,740,000 | 73,163,000 | 56,224,000 | 45,653,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-70,371,000
Investing CF
$0
Financing CF
$67,904,000
CapEx
$-268,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.39
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-449,048,000
Inventory
—
Receivables
$22,000
ST Investments
—
EBIT TTM
$-81,307,000
Pretax Income TTM
$-61,797,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,307,000 | -61,797,000 | 58,572,000 | 29,020,000 | — | -70,371,000 |
| Dec 2024 | 0 | -144,070,000 | -138,426,000 | 79,938,000 | 28,365,000 | — | -119,894,000 |
| Dec 2023 | 0 | -126,135,000 | -117,255,000 | 199,927,000 | 30,690,000 | — | -96,592,000 |
| Dec 2022 | 0 | -83,634,000 | -81,828,000 | 129,307,000 | 20,768,000 | — | -62,417,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZOMDF | Zomedica Corp. | $102.40M | $0.10 | — |
| RVRC | Revium Rx. | $101.42M | $1.67 | — |
| PYXS | Pyxis Oncology, Inc. | $103.27M | $1.63 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $103.42M | $6.02 | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $103.66M | $1.26 | — |
News headlines (Yahoo Finance, 1h cache)
Biomea Fusion to Participate at Upcoming Investor Conferences
2026-05-12 20:05 · Yahoo
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-11 20:54 · Yahoo
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
2026-05-05 21:50 · Yahoo
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026
2026-05-05 20:20 · Yahoo
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
2026-04-28 20:31 · Yahoo
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
2026-04-27 21:37 · Yahoo
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
2026-03-31 11:00 · Yahoo
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
2026-03-30 21:03 · Yahoo
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes
2026-03-30 18:24 · Yahoo
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?
2026-03-27 10:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.